PreCision Dermatology (www.precisionderm.com) has acquired the assets of Triax Pharmaceuticals, a company that markets branded prescription dermatology products, including topical steroid Locoid, and acne treatments Minocin and Tretin X.
Triax Pharmaceuticals' products will join the Onset Dermatologics portfolio, a prescription dermatology subsidiary of PreCision Dermatology. PreCision is led by Jeffrey Nugent, the former president and CEO of Neutrogena and former president and CEO of Revlon.
“We are extremely pleased to add these brands to the Onset Dermatologics' portfolio. The combination of these product groups is an excellent fit that enhances our focus in the atopic dermatitis and acne therapeutic categories,” said Mr. Nugent. “Our Onset sales and marketing team is among the best in dermatology and I'm confident that these products will continue to gain the trust of physicians across the country.”
A group of investors led by Essex Woodlands, MidCap Financial and new investor, NovaQuest Capital Management supported the acquisition.